Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

The finding, from a study with a mean follow-up of 2-and-a-half years, bolsters support for trials and device use to continue.

News Daily News

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

December 18, 2020

As Paclitaxelgate Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

News Conference News VIVA 2020

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

November 27, 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

October 18, 2020

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

September 17, 2020

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

News Daily News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

June 29, 2020

Recovered Paclitaxel PAD Data Shift the Mortality Picture

News Daily News

Recovered Paclitaxel PAD Data Shift the Mortality Picture

May 14, 2020

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

News Daily News

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

March 09, 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

January 28, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

January 24, 2020

News Daily News

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

January 15, 2020

The Biggest News of 2019: TCTMD’s Top 10

News Opinion Editor's Corner

The Biggest News of 2019: TCTMD’s Top 10

January 01, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.